Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
A Prospective, Multicenter，Phase II Clinical Study of Trastuzumab and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
Sponsor: Tianjin Medical University Cancer Institute and Hospital
This NA trial investigates HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy and is currently ongoing. Tianjin Medical University Cancer Institute and Hospital leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Sep 2025 [monthly]
Not Yet Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting NA
-
Nov 2022 — Jul 2024 [monthly]
Not Yet Recruiting NA
-
Oct 2022 — Nov 2022 [monthly]
Not Yet Recruiting NA
First recorded
Sep 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tianjin Medical University Cancer Institute and Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.